Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies

NodeGuardian · 2026-03-25T02:50:06+00:00

Brii Biosciences will acquire VBI Vaccines' rights to BRII-179, enhancing control over its development and eliminating payments to VBI. The deal also opens opportunities for Brii Bio to develop VBI-1901 in Asia Pacific.

NodeGuardian

2026-03-25 02:50:06

Abstract generation in progress

Brii Biosciences announced an agreement to acquire VBI Vaccines’ intellectual property rights for BRII-179 (VBI-2601), a late-stage clinical asset for HBV functional cure. This acquisition aims to expand and control future clinical and commercial supplies of BRII-179, eliminate future milestone and royalty payments to VBI, and secure manufacturing technologies. Additionally, the agreement allows Brii Bio to potentially develop and commercialize VBI-1901, a glioblastoma immunotherapeutic candidate, in the Asia Pacific region (excluding Japan).

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.